Takeda posts downturn in sales for FY 2012; forecasts operating profit slump

Japan’s largest drugmaker, Takeda Pharmaceutical (TYO: 4502) posted disappointing results for its fiscal year ended March 31, 2012, with a 0.9% decline in revenues to 834.71 billion yen ($10,45 billion) and operating profit falling 2% to 178.81 billion yen. However, current profit leapt 132.9% to 451.68 billion yen and net income rocketed 174.2% to 372.52 yen, or 471.86 yen per share.

The company’s shares fell 4.6% to 3,245 yen (the biggest fall in 14 months according to Bloomberg), as Takeda also announced mid term plans forecasting a 40% drop in operating profit due to acquisition costs and increased R&D expenditure, which came as a big surprise to the market.

FY2012 product performance mixed